Analysis of changes in patients with advanced cervical cancer before and after treatment with albumin-bound paclitaxel combined with cisplatin
Objective To analyze the changes in patients with advanced cervical cancer before and after treatment with albumin-bound paclitaxel combined with cisplatin.Methods 100 patients with advanced cervical cancer were randomly divided into a study group and a control group,with 50 cases in each group.Both groups received the prescribed treatment regimen of simultaneous chemoradiotherapy.The study group was treated with paclitaxel injection(albumin-bound)in combination with cisplatin chemotherapy,while the control group was treated with solvent-based paclitaxel in combination with cisplatin chemotherapy.Patients in both groups were compared in terms of severity of disease remission,occurrence of adverse reactions(decreased hemoglobin,thrombocytopenia,leukopenia,neutropenia,gastrointestinal reaction,abnormal liver function),tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)before and after treatment),carbohydrate antigen 125(CA125)]level,disease deterioration and survival within 2 years.Results After treatment,the total remission rate of the treatment group was 66.00%,which was higher than 46.00%of the control group,and the difference was statistically significant(P<0.05).The incidence of gastrointestinal reactions in the study group was 16.00%,which was lower than 34.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the study group had CEA of(8.05±1.19)U/ml,SCC-Ag of(1.86±0.41)ng/ml,CYFRA21-1 of(8.11±1.52)ng/ml,and CA125 of(26.32±2.86)U/ml,which were lower than(8.86±1.38)U/ml,(2.13±0.49)ng/ml,(9.03±1.85)ng/ml,and(27.64±3.13)U/ml in the control group.The difference was statistically significant(P<0.05).The deterioration rate of the study group within 2 years after treatment was 46.00%,which was lower than 66.00%of the control group;the survival rate of the study group was 82.00%,which was higher than 64.00%of the control group;the time to deterioration of the study group was(1.15±0.54)years,and the time of death was(1.48±0.46)years,which were later than(0.91±0.52)and(1.23±0.45)years of the control group.The difference was statistically significant(P<0.05).Conclusion Application of albumin-bound paclitaxel combined with cisplatin in patients with advanced cervical cancer can increase the degree of lesion remission,reduce gastrointestinal reactions,reduce the incidence of disease deterioration in the short term after treatment,while improving patient survival.
万方数据
维普
